Farxiga vs Victoza
A side-by-side look at two diabetes medications advertised on TV. Informational only — not medical advice.
| US Farxiga | US Victoza | |
|---|---|---|
| Generic name | dapagliflozin | liraglutide |
| Drug class | SGLT2 Inhibitor | GLP-1 Receptor Agonist |
| Treats | Type 2 diabetes, heart failure, chronic kidney disease | Type 2 diabetes |
| Category | Diabetes | Diabetes |
| Manufacturer | AstraZeneca | Novo Nordisk |
| Year approved | 2014 | 2010 |
| FDA warning | No boxed warning | Black box warning |
| Est. TV ad spend | $220M | — |
| Common side effects | Genital yeast infections, Urinary tract infections, Dehydration, Low blood pressure | Nausea, Diarrhea, Headache, Risk of thyroid C-cell tumors (boxed warning) |
Frequently asked questions
Is Farxiga or Victoza better?
Neither is universally "better." Farxiga (dapagliflozin) and Victoza (liraglutide) are both used for diabetes, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Farxiga and Victoza?
Farxiga is a SGLT2 Inhibitor made by AstraZeneca, while Victoza is a GLP-1 Receptor Agonist made by Novo Nordisk. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Farxiga has the larger estimated TV advertising budget of the two.